This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gayle, H. D.
Right arrow Articles by Hill, G. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gayle, H. D.
Right arrow Articles by Hill, G. L.

 Previous Article  |  Next Article 

Clinical Microbiology Reviews, April 2001, p. 327-335, Vol. 14, No. 2
0893-8512/01/$04.00+0   DOI: 10.1128/CMR.14.2.327-335.2001

Global Impact of Human Immunodeficiency Virus and AIDS

Helene D. Gayle and Gena L. Hill*

National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia 30333

This review provides information on the epidemiology, economic impact, and intervention strategies for the human immunodeficiency virus (HIV)/AIDS pandemic in developing countries. According to the World Health Organization and the Joint United Nations Programme on HIV/AIDS (UNAIDS) at the end of 1999, an estimated 34.3 million people were living with HIV/AIDS. Most of the people living with HIV, 95% of the global total, live in developing countries. Examples of the impact of HIV/AIDS in Africa, Asia, Latin America, the Caribbean, and the Newly Independent States provide insight into the demographics, modes of exposure, treatment and prevention options, and the economic effect of the epidemic on the global community. The epidemic in each region of the world is influenced by the specific risk factors that are associated with the spread of HIV/AIDS and the responses that have evolved to address it. These influences are important in developing HIV/AIDS policies and programs to effectively address the global pandemic.

* Corresponding author. Phone: (404) 639-8000. Fax: (404) 639-8600. E-mail: ghill{at}cdc.gov. Reprint requests: Office of Communications, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Rd. NE, Mailstop E-06, Atlanta, GA 30333.

Clinical Microbiology Reviews, April 2001, p. 327-335, Vol. 14, No. 2
0893-8512/01/$04.00+0   DOI: 10.1128/CMR.14.2.327-335.2001


This article has been cited by other articles:

  • Beer, B. E., Doncel, G. F., Krebs, F. C., Shattock, R. J., Fletcher, P. S., Buckheit, R. W. Jr., Watson, K., Dezzutti, C. S., Cummins, J. E., Bromley, E., Richardson-Harman, N., Pallansch, L. A., Lackman-Smith, C., Osterling, C., Mankowski, M., Miller, S. R., Catalone, B. J., Welsh, P. A., Howett, M. K., Wigdahl, B., Turpin, J. A., Reichelderfer, P. (2006). In Vitro Preclinical Testing of Nonoxynol-9 as Potential Anti-Human Immunodeficiency Virus Microbicide: a Retrospective Analysis of Results from Five Laboratories. Antimicrob. Agents Chemother. 50: 713-723 [Abstract] [Full Text]  
  • Fichorova, R.N., Bajpai, M., Chandra, N., Hsiu, J.G., Spangler, M., Ratnam, V., Doncel, G.F. (2004). Interleukin (IL)-1, IL-6, and IL-8 Predict Mucosal Toxicity of Vaginal Microbicidal Contraceptives. Biol. Reprod. 71: 761-769 [Abstract] [Full Text]  
  • Herring, B. L., Ge, Y. C., Wang, B., Ratnamohan, M., Zheng, F., Cunningham, A. L., Saksena, N. K., Dwyer, D. E. (2003). Segregation of Human Immunodeficiency Virus Type 1 Subtypes by Risk Factor in Australia. J. Clin. Microbiol. 41: 4600-4604 [Abstract] [Full Text]  
  • (2001). The Global HIV and AIDS Epidemic, 2001. JAMA 285: 3081-3083 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»